Ascensia Diabetes Care, a PHC Holdings subsidiary, today announced the launch of its Contour Comfort pen needles. The Basel, Switzerland-based company said the launch further strengthens its Contour portfolio with a solution that improves the everyday injection experience. It marks the company’s entry into the pen needle category. Ascensia designed Contour Comfort pen needles to […]
Ascensia Diabetes Care
Ascensia Diabetes Care has a new CEO
Ascensia Diabetes Care, a PHC Holdings subsidiary, today announced the appointment of Peter Bodlund as president and CEO. Bodlund succeeds Koichiro Sato, effective April 1, 2026. Sato continues in his roles as COO of the PHC Group and head of PHC Group’s Diabetes Management business. An experienced leader across global healthcare and life sciences organizations, […]
What diabetes tech companies are doing on World Diabetes Day 2025
Once again, World Diabetes Day, celebrated on Nov. 14 every year, has come around, highlighting new initiatives in the diabetes tech space. The date marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. It also lands during the American Diabetes Association’s National Diabetes Awareness Month. […]
Senseonics to take over commercial efforts for Eversense 365 from Ascensia
Senseonics (NYSE:SENS) announced today that it entered into an agreement with Ascensia Diabetes Care to take over commercialization efforts for its products. The companies entered into a mutually executed memorandum of understanding. This agreement transitions all commercialization and distribution of the Eversense 365 long-term implantable continuous glucose monitor (CGM) and future products from Ascensia to […]
Senseonics lays out hopes for next-gen CGM commercial timelines
Senseonics (NYSE:SENS) has offered some insight into its plans for its next-generation implantable continuous glucose monitors (CGMs). The maker of the Eversense 365 year-long implantable CGM hosted an analyst event during the American Diabetes Association’s 85th Scientific Sessions in Chicago this past weekend. At that event, the company touched on the commercial strategy for Eversense […]
Senseonics expects to double global patient base in 2025, progresses with pump integration
Senseonics (NYSE:SENS) shares ticked up after hours today on fourth-quarter results that came in ahead of the consensus forecast. Shares of SENS went up nearly 7% to 93¢ apiece in post-market trading today. The Germantown, Maryland-based long-term implantable continuous glucose monitor maker reported losses of $15.5 million for the quarter. That equals losses 2¢ per […]
Ascensia Diabetes Care creates “wellness zone” for World Diabetes Day
Ascensia Diabetes Care today announced its plans to recognize World Diabetes Day 2024 with a virtual diabetes campaign. World Diabetes Day — Nov. 14 — recognizes the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. November is also the American Diabetes Association’s National Diabetes Awareness Month. […]
What diabetes tech companies are doing on World Diabetes Day 2024
World Diabetes Day — today, Nov. 14 — brings out the best in the diabetes community that continues to innovate year after year. This date serves as a time to recognize these innovations as it marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. The […]
Senseonics, Ascensia launch Eversense 365 year-long CGM in the U.S.
Ascensia Diabetes Care announced today that it launched the Eversense 365 CGM system from Senseonics (NYSE:SENS) in the U.S. Eversense 365, an implantable continuous glucose monitor (CGM), is indicated for people with type 1 and type 2 diabetes aged 18 years and older. Senseonics announced last month that it received FDA clearance for Eversense 365. With […]
Senseonics wins FDA nod for 365-day implantable CGM
Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system. Eversense 365, an implantable continuous glucose monitor (CGM), becomes the world’s first 365-day CGM system, according to the company. Its indications cover people with type 1 and type 2 diabetes aged 18 years and older. The system also received clearance […]
